产品名称

英文名称：CUDC-907

同义词

CUDC-907、Fimepinostat、1339928-25-4、CUDC 907、CUDC907、PI3K/HDAC Inhibitor、Fimepinostat [USAN]、N-hydroxy-2-[[2-(6-methoxypyridin-3-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxamide、N-hydroxy-2-(((2-(6-methoxypyridin-

产品性质

CAS编号：1339928-25-4

分子式：C23H24N8O4S

分子量：508.55

PubChem编号：54575456

英文别名：CUDC-907|Fimepinostat|1339928-25-4|CUDC 907|CUDC907|PI3K/HDAC Inhibitor|Fimepinostat [USAN]|N-hydroxy-2-[[2-(6-methoxypyridin-3-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxamide|N-hydroxy-2-(((2-(6-methoxypyridin-

规格或纯度：98%

英文名称：CUDC-907

生化机理：Description IC50 Value 1.7/5.0/1.8/2.8 nM (HDAC1/2/3/10); 19/54/39 nM (PI3Kα/β/δ) CUDC-907 potently inhibits class I PI3Ks as well as classes I and II HDAC enzymes. in vitro CUDC-907 induced the accumulation of acetylated histone H3, tubulin, and p53, as well as p21 expression in a dose-dependent manner (Supplementary Figs. S2-S5). Similarly, we observed that CUDC-907 inhibited the PI3K pathway, as indicated by the dose-dependent decreases in phosphorylation of AKT and its downstream targets, 4EBP-1 and p70S6, in H460 cells. CUDC-907 induced caspase-3 and -7 activation in HCT-116 colon cancer cells in a dose-dependent manner . in vivo oral administration of CUDC-907 inhibited growth of the Daudi cancer cell xenografts in a dose-dependent manner. Tumor stasis was observed at 100 mg/kg in this model without obvious toxicity. Furthermore, CUDC-907 caused tumor regression or stasis after intravenous (50 mg/kg) or oral administration (100 mg/kg) in a xenograft tumor model of SU-DHL4 diffuse large B-cell lymphoma (DLBCL) and caused tumor stasis in KRAS-mutant A549 NSCLC cell xenografts Toxicity oral administration of CUDC-907 inhibited growth of the Daudi cancer cell xenografts in a dose-dependent manner. Tumor stasis was observed at 100 mg/kg in this model without obvious toxicity . Clinical trial Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Patients With Lymphoma or Multiple Myeloma.

储存温度：-20°C储存

运输条件：超低温冰袋运输

产品介绍：产品介绍CUDC-907是一种PI3K和HDAC双重抑制剂，作用于PI3Kα和HDAC1/2/3/10，IC50分别为19 nM和1.7 nM/5 nM/1.8 nM/2.8 nM。CUDC-907 在乳腺癌细胞中可诱导细胞周期阻滞与凋亡。

ALogP：1.3

IUPAC Name：N-hydroxy-2-[[2-(6-methoxypyridin-3-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxamide

INCHI：InChI=1S/C23H24N8O4S/c1-30(23-25-11-15(12-26-23)22(32)29-33)13-16-9-17-19(36-16)21(31-5-7-35-8-6-31)28-20(27-17)14-3-4-18(34-2)24-10-14/h3-4,9-12,33H,5-8,13H2,1-2H3,(H,29,32)

InChi Key：JOWXJLIFIIOYMS-UHFFFAOYSA-N

Canonical SMILES：CN(CC1=CC2=C(S1)C(=NC(=N2)C3=CN=C(C=C3)OC)N4CCOCC4)C5=NC=C(C=N5)C(=O)NO

Isomeric SMILES：CN(CC1=CC2=C(S1)C(=NC(=N2)C3=CN=C(C=C3)OC)N4CCOCC4)C5=NC=C(C=N5)C(=O)NO

PubChem CID：54575456

CAS Registry No.：1339928-25-4

溶解性：DMSO 102 mg/mL Water <1 mg/mL Ethanol <1 mg/mL

产品包装